Pulmozyme Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to established efficacy in aat deficiency, pulmonology guideline support, plasma derived protein availability, specialist prescription patterns, improved disease management outcomes.

The growth in the forecast period can be attributed to increasing genetic screening programs, rising copd burden, expansion of specialty respiratory care, improved patient adherence, growth of plasma collection infrastructure. Major trends in the forecast period include rising adoption of augmentation therapy, focus on preventing copd progression, long term plasma protein replacement use, hospital and specialty clinic administration, growth in genetic lung disorder awareness.

The rising prevalence of respiratory disorders is expected to drive the growth of the Pulmozyme market in the coming years. Respiratory disorders are medical conditions that affect the lungs and airways, impairing breathing and oxygen exchange, and include diseases such as asthma, COPD, and pneumonia. The increase in these disorders is fueled by factors such as air pollution, smoking, occupational hazards, climate change, and higher exposure to allergens and infectious agents. Pulmozyme (dornase alfa) is used to manage respiratory conditions like cystic fibrosis by breaking down thick mucus in the lungs, improving airflow, and reducing the risk of infections. For instance, in June 2024, the Australian Institute of Health and Welfare, an Australia-based health agency, reported that approximately 8.5 million Australians, or 34% of the population, had chronic respiratory conditions. This includes an estimated 2.8 million people (11%) living with asthma and 638,000 people (2.5%) living with chronic obstructive pulmonary disease (COPD). Therefore, the rising prevalence of respiratory disorders is driving the Pulmozyme market.

The growing number of lung transplants is also expected to support the expansion of the Pulmozyme market. A lung transplant is a surgical procedure in which a diseased or failing lung is replaced with a healthy donor lung to treat severe respiratory failure or chronic lung diseases. The rise in lung transplants is driven by increasing prevalence of chronic respiratory diseases such as cystic fibrosis and COPD, improvements in surgical techniques, and advancements in post-transplant care that enhance survival rates. Pulmozyme, a recombinant human DNase enzyme, benefits lung transplant patients by breaking down thick, sticky mucus in the airways, reducing the risk of infections, and improving lung function, thereby supporting better respiratory health post-transplant. For example, in August 2023, the UK National Health Service (NHS) reported that the number of UK citizens with active lung and heart-lung transplants increased from 267 in 2022 to 302 in 2023. Therefore, the increase in lung transplants is driving the Pulmozyme market.

Key companies in the cystic fibrosis treatment device market are focusing on developing advanced delivery solutions, such as vibrating mesh nebulizers, to improve drug delivery, enhance treatment adherence, and elevate patient quality of life. Vibrating mesh nebulizers use a fine mesh to generate a consistent aerosol, allowing more efficient and targeted delivery of medications like Pulmozyme to the lungs. For example, in March 2024, HCmed, a Taiwan-based medical technology company, announced that its Pulmogine Vibrating Mesh Nebulizer received FDA approval for use with Pulmozyme, becoming one of only five FDA-approved mesh nebulizer devices compatible with this therapy. This development highlights the market’s focus on innovative delivery devices that optimize therapy outcomes and patient experience.

Major companies operating in the pulmozyme market are Roche Holding AG.

North America was the largest region in the pulmozyme market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmozyme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pulmozyme market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the prolastin-c market by increasing costs associated with plasma sourcing, purification technologies, and biologic cold chain distribution. These impacts are most pronounced in regions dependent on imported plasma derived therapies such as Asia Pacific and parts of Europe. Hospitals and specialty clinics face higher treatment acquisition costs. Regulatory compliance and customs clearance have added complexity to supply chains. At the same time, tariffs are encouraging domestic plasma fractionation investments and enhancing long term supply stability.

The pulmozyme market research report is one of a series of new reports that provides pulmozyme market statistics, including pulmozyme industry global market size, regional shares, competitors with a pulmozyme market share, detailed pulmozyme market segments, market trends and opportunities, and any further data you may need to thrive in the pulmozyme industry. This pulmozyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pulmozyme (Dornase alfa) is a recombinant human deoxyribonuclease I (DNase I) enzyme primarily used to treat cystic fibrosis (CF). It works by breaking down DNA in the thick mucus of the lungs, reducing mucus viscosity, improving lung function, and facilitating easier breathing. Administered via a nebulizer, Pulmozyme also helps lower the risk of respiratory infections.

The main indications for Pulmozyme are cystic fibrosis and respiratory tract infections. This genetic disorder leads to the accumulation of thick, sticky mucus in the lungs and digestive system, causing breathing difficulties and recurring lung infections. Pulmozyme is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by end-users in hospitals, clinics, and homecare settings.

The pulmozyme market consists of sales of inhalation solutions, nebulizer solutions, and injectable solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.